Categories: News

Published Study Shows Clinically Significant Energy, Performance, and Metabolic Benefits of FutureCeuticals’ Caffinity

MOMENCE, Ill., June 10, 2026 /PRNewswire/ — FutureCeuticals, Inc. is pleased to announce the peer-reviewed publication of clinical research demonstrating unique energy, performance, and metabolic benefits of Caffinity™, a proprietary ingredient derived from the Arabica coffee cherry (bean and fruit). This study, conducted by recognized experts in energy metabolism at the University of Exeter (UK), establishes Caffinity as the only clinically validated energy ingredient to deliver a natural complex of caffeine and polyphenols from coffee fruit, enhancing athletic performance and metabolic recovery, while avoiding some of the known downsides from functional doses of caffeine.

- Advertisement -

In the double-blind, placebo-controlled study, a 286mg dose of Caffinity (providing 200mg of caffeine along with coffee fruit polyphenols) significantly improved time trial performance in trained cyclists, yielding a nearly 5% average increase in total work performed compared to placebo (P <0.05). Participants also reported reduced perceived exertion during a preceding bout of sub-maximal steady-state exercise, highlighting benefits across a range of exercise intensity.

- Advertisement -

Researchers observed additional unexpected outcomes, perhaps attributable to Caffinity’s unique composition. Caffinity stimulated an increase in fat mobilization and ketone availability during recovery, priming the body for enhanced metabolic flexibility. Caffinity also helped stabilize blood glucose, avoiding the spikes and crashes often associated with functional caffeine doses and intra-exercise fueling. Despite higher work output, post-exercise lactate cleared more rapidly, returning to baseline sooner and promoting quicker recovery.

- Advertisement -

“These results support our commitment to deliver clean, science-backed, low-dosed energy solutions that meet the needs of today’s active consumer,” said J. Randal Wexler, General Counsel and VP of R&D at FutureCeuticals. “Caffinity not only enhances performance, it also demonstrates better metabolic recovery and glucose stability than typically associated with functional doses of caffeine.” Mr. Wexler concluded, “For athletes looking to optimize their performance nutrition strategies, Caffinity is a new tool to reduce stimulant exposure without sacrificing results.”

- Advertisement -

Caffinity is made from sustainably sourced coffee fruit from family farms. Unlike synthetic caffeine or isolated extracts, Caffinity delivers a caffeine and polyphenol complex from coffee fruit standardized to 70% natural caffeine and 5% natural polyphenols.

- Advertisement -

About FutureCeuticals, Inc.

- Advertisement -

FutureCeuticals, Inc. is the exclusive developer of Caffinity™ and a leader in the research, development and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.

- Advertisement -

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/published-study-shows-clinically-significant-energy-performance-and-metabolic-benefits-of-futureceuticals-caffinity-302795818.html

- Advertisement -

Recent Posts

ICFAI Business School Opens IBSAT 2026 Registrations, Announces 10 Crore Scholarship Program

HYDERABAD, India, July 1, 2026 /PRNewswire/ -- ICFAI Business School (IBS) opened the registration process for…

4 hours ago

FitsAir and Amadeus sign global distribution agreement to expand international reach

COLOMBO, Sri Lanka, July 1, 2026 /PRNewswire/ -- FitsAir, Sri Lanka's privately owned international airline,…

4 hours ago

MEXC SpaceX Products See Surging Demand as Cumulative Futures Trading Volume Surpasses $7.1 Billion

VICTORIA, Seychelles, June 30, 2026 /PRNewswire/ -- MEXC, a pioneer in 0-fee digital asset trading,…

4 hours ago

STARTRADER Launches Pre-IPO Trading Products for OpenAI and Anthropic

The new CFD instruments give traders early exposure to two of the world's most prominent…

4 hours ago

Apollo Hospitals, Bangalore Becomes First in India to Receive Dual American Heart Association Certification for Stroke and Chest Pain Care

BENGALURU, India, June 30, 2026 /PRNewswire/ -- Apollo Hospitals, Bangalore has become the first hospital in…

8 hours ago

Basecamp Research brings EDEN’s antibiotic and vaccine design models to Claude Science

Scientists can now design potent antibiotics and rapidly prioritise vaccine targets through Claude Science, thanks…

10 hours ago